Pituitary Adenoma

📋 Key Information Summary

📋

Pituitary adenomas are benign monoclonal tumours of the anterior pituitary gland, classified by size (microadenoma <10 mm, macroadenoma ≥10 mm) and functional status (secretory vs. non-functioning).
Prevalence on high-resolution MRI is approximately 10–15%, but clinically significant tumours are less common, accounting for ~15% of intracranial neoplasms.
Mass effects from macroadenomas include bitemporal hemianopia, headache, and hypopituitarism due to stalk compression.
Prolactinoma is the most common secretory adenoma (40–60%); first-line medical therapy is a dopamine agonist (cabergoline).
Acromegaly (GH excess) and Cushing's disease (ACTH excess) require multidisciplinary management, with transsphenoidal surgery as first-line for most.
Pituitary function testing (prolactin, IGF-1, cortisol, thyroid/sex hormones, α-subunit) is essential for all macroadenomas and symptomatic microadenomas.
MRI with dedicated pituitary protocol (gadolinium-enhanced, 1–1.5T minimum) is the gold-standard imaging investigation.
Visual field assessment (formal perimetry) is mandatory for any adenoma abutting or compressing the optic chiasm.
Management is stratified: prolactinomas → medical; most other adenomas → surgery (endoscopic endonasal transsphenoidal); recurrent/residual disease → radiotherapy or medical therapy.
Lifelong endocrine surveillance is required post-treatment for recurrence, hypopituitarism, and comorbidities (cardiovascular, metabolic).
Pregnancy planning is critical in fertile women with prolactinomas or Cushing's disease, requiring pre-conception medication adjustment and monitoring.
Aboriginal and Torres Strait Islander peoples may face delayed diagnosis and barriers to specialist care; culturally safe, accessible services are essential.

🎧 Audio Brief

How pituitary tumors change your body

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Pituitary adenomas are benign neoplasms arising from the anterior pituitary gland (adenohypophysis). They represent approximately 10–15% of intracranial neoplasms and are the most common sellar mass. Autopsy and radiological (MRI) studies suggest a prevalence of 10–15%, though the majority are incidental, non-functioning microadenomas without clinical significance.

In Australia, the incidence of clinically relevant pituitary adenomas is estimated at 3–5 per 100,000 population per year. Data from the Australian Institute of Health and Welfare (AIHW) and specialist centres (e.g., Royal Melbourne Hospital, Westmead Hospital) indicate that prolactinomas account for 40–60% of all secretory adenomas, followed by non-functioning adenomas (15–30%), GH-secreting adenomas (acromegaly, 10–15%), and ACTH-secreting adenomas (Cushing's disease, 5–10%). Thyroid-stimulating hormone (TSH)-secreting adenomas are rare (<1%).

Management requires a multidisciplinary pituitary team including an endocrinologist, neurosurgeon, neuroradiologist, ophthalmologist, and radiation oncologist. Early recognition and appropriate referral are crucial to prevent irreversible complications such as hypopituitarism, visual loss, and the metabolic and cardiovascular consequences of hormonal hypersecretion.

Pituitary Adenoma clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management — Tap or click image to enlarge — Pituitary Adenoma: pathophysiology, clinical clues, diagnosis, imaging, and management.

Classification & Pathophysiology

Classification by Size

Microadenoma: <10 mm in diameter. Typically confined to the sella turcica; rarely cause mass effects.
Macroadenoma: ≥10 mm in diameter. May extend suprasellarly, laterally into cavernous sinuses, or inferiorly into sphenoid sinus. Responsible for most mass-effect symptoms.
Giant adenoma: >40 mm; rare but associated with higher surgical morbidity.

Classification by Function

Type	Hormone Excess	Proportion	Key Pathophysiology
Prolactinoma	Prolactin	40–60%	Direct dopamine inhibition by tumour; galactorrhoea, hypogonadism.
Somatotrophinoma	Growth Hormone (GH)	10–15%	GH → hepatic IGF-1 excess; acral enlargement, metabolic dysfunction.
Corticotrophinoma	ACTH	5–10%	ACTH drives adrenal cortisol hypersecretion; central obesity, hypertension.
Non-functioning adenoma	None (or subclinical α-subunit)	15–30%	Mass effect; often macroadenoma at presentation.
Thyrotrophinoma	TSH	<1%	Inappropriate TSH secretion causing central hyperthyroidism.

Histopathological Classification (WHO 2022)

The modern WHO classification emphasises immunohistochemistry for pituitary transcription factors (PIT-1, T-PIT, SF-1) and hormone production, moving away from the term "adenoma" to "pituitary neuroendocrine tumour (PitNET)" in some contexts. Prognostic markers include mitotic count, Ki-67 proliferation index (>3% suggests potential for more aggressive behaviour), and p53 expression.

Clinical Features (Mass Effect, Hormonal)

Mass Effect Symptoms (Macroadenomas)

Visual field defects: Classically bitemporal hemianopia due to chiasmal compression. May progress to blindness. Formal perimetry is essential.
Headache: Often frontal or retro-orbital due to dural stretching. Not always correlated with tumour size.
Cranial nerve palsies: Diplopia from III, IV, VI nerve involvement if lateral extension into cavernous sinus.
Apoplexy: Sudden haemorrhage or infarction within the adenoma. Presents with acute headache, visual loss, ophthalmoplegia, and potential cardiovascular collapse (adrenal crisis). Requires emergency high-dose glucocorticoids and neurosurgical assessment.
Hypopituitarism: Compression of normal pituitary tissue and stalk. Sequence of loss typically: GH > FSH/LH > TSH > ACTH. Presents with fatigue, amenorrhoea, erectile dysfunction, cold intolerance.

Syndromes of Hormonal Excess

Prolactinoma

Female

Oligomenorrhoea/amenorrhoea, galactorrhoea, infertility, reduced libido. Microadenomas common.

Setting: Endocrine clinic

Prolactinoma

Male

Erectile dysfunction, reduced libido, infertility, gynaecomastia. Often presents late as macroadenoma.

Setting: Endocrine/Urology clinic

Acromegaly

GH/IGF-1 Excess

Gradual coarsening of facial features, prognathism, macroglossia, soft tissue swelling, arthralgia, carpal tunnel syndrome, sweating, sleep apnoea, diabetes, hypertension, cardiomyopathy.

Setting: Multidisciplinary pituitary clinic

Cushing's Disease

ACTH Excess

Central obesity, moon face, supraclavicular fat pads, proximal myopathy, purple striae, easy bruising, hypertension, hyperglycaemia, osteoporosis, depression, psychosis.

Setting: Specialist endocrine unit

Investigations (MRI Pituitary, Hormone Profile)

Biochemical / Hormonal Profile

Essential for all macroadenomas and symptomatic microadenomas. Perform in a specialised endocrine laboratory.

Essential

Serum Prolactin

Elevated >20 µg/L (women), >15 µg/L (men). Macroprolactinomas: often >1000 µg/L. Rule out "hook effect" in giant tumours.

Essential

Insulin-like Growth Factor-1 (IGF-1)

Age- and sex-adjusted. Elevated in acromegaly. First-line screen for GH excess.

Essential

Oral Glucose Tolerance Test (OGTT) for GH

Confirmatory for acromegaly: failure to suppress GH to <1 µg/L (or <0.4 µg/L with ultrasensitive assay) after 75g glucose load. MBS Item 66660.

Essential

24-hour Urinary Free Cortisol & Late-night Salivary Cortisol

Screen for Cushing's syndrome. Require at least two abnormal tests. MBS Items 66655, 66658.

Available

Low-dose Dexamethasone Suppression Test (LDDST)

Confirmatory for Cushing's: 1 mg dex overnight; serum cortisol >50 nmol/L suggests Cushing's. MBS Item 66654.

Essential

Thyroid Function Tests, Testosterone/Oestradiol, LH, FSH

Assess for hypopituitarism and hyperthyroidism (TSHoma).

Available

Dynamic Pituitary Function Testing (Insulin Tolerance Test, GnRH Stimulation)

Gold standard for GH and ACTH reserve. Perform in specialist centre with endocrine nurse supervision. MBS Item 66670.

Radiology

Essential

MRI Pituitary with Gadolinium (Dedicated Protocol)

1–1.5T (3T preferred) with thin coronal and sagittal T1-weighted sequences pre- and post-gadolinium. Identifies tumour size, invasion (cavernous sinus, sphenoid), and relationship to optic chiasm. MBS Item 63000 series.

Referral

CT Scan (if MRI contraindicated)

For bony anatomy of sella, or if MRI contraindicated (e.g., pacemaker).

Ophthalmology

Essential

Formal Visual Field Perimetry (Humphrey)

Mandatory for any macroadenoma within 2 mm of optic chiasm. Baseline and post-operative monitoring.

Available

Optical Coherence Tomography (OCT)

Measures retinal nerve fibre layer thickness; objective measure of chiasmal compression.

Management (Surgery, Radiotherapy, Medical)

General Principles

Management is determined by adenoma type, size, invasiveness, and patient factors. All patients should be discussed at a multidisciplinary pituitary tumour board (neuroendocrinology, neurosurgery, neuroradiology, radiation oncology, ophthalmology).

⚠️

Pituitary Apoplexy: Medical emergency. Immediate high-dose dexamethasone (4–6 mg IV 6-hourly), fluid resuscitation, and urgent neurosurgical assessment for visual deterioration or declining consciousness. Do not delay steroids for imaging.

Medical Therapy

💊

Cabergoline

Dostinex® · Dopamine agonist (D2)

Indication First-line for prolactinomas (micro and macro). Also used in acromegaly adjunctively.

Adult dose 0.25–0.5 mg PO twice weekly, titrate to normalise prolactin (max 3 mg/week).

Paediatric dose Safety and efficacy not established in paediatric prolactinoma.

Key monitoring Prolactin monthly until normal, then 6–12 monthly. Cardiac echo at baseline and after 5 years (mitral valve regurgitation risk at high dose >2 mg/week).

PBS status ✔ PBS General Benefit

💊

Octreotide LAR / Lanreotide Autogel

Sandostatin LAR® / Somatuline Autogel® · Somatostatin analogue (SRL)

Indication Second-line for acromegaly (if surgery not curative or not feasible). First-line for TSHomas.

Adult dose Octreotide LAR 20 mg IM monthly, titrate to 30 mg. Lanreotide 60–120 mg deep SC monthly.

Key monitoring IGF-1 and GH every 3–6 months. Cholelithiasis screen (ultrasound) annually. Fasting glucose.

PBS status ⚠ PBS Authority Required (Acromegaly, TSHoma)

💊

Pegvisomant

Somavert® · GH receptor antagonist

Indication Third-line for acromegaly refractory to surgery and SRLs. Normalises IGF-1 in >90%.

Adult dose Loading 80 mg SC, then 10–15 mg SC daily. Titrate based on IGF-1.

Key monitoring LFTs monthly for 6 months, then 6-monthly. IGF-1 every 4–6 weeks until normal. Monitor tumour size (may increase).

PBS status ✖ Not PBS (Very high cost ~$50,000/year)

Surgical Therapy

Endoscopic Endonasal Transsphenoidal Surgery (EETS) is the gold-standard approach for most pituitary adenomas. Performed by a specialised skull-base neurosurgeon.

Indications: All non-prolactinoma secretory adenomas (first-line), non-functioning adenomas causing mass effect, prolactinomas resistant/intolerant to dopamine agonists, pituitary apoplexy with visual compromise.
Remission rates: Microadenomas 70–90%, Macroadenomas 40–70% (higher for experienced surgeons). Higher for invasive tumours.
Complications: CSF leak (2–5%), new hypopituitarism (5–15%), diabetes insipidus (transient 10–20%, permanent 1–2%), meningitis, vascular injury (<1%).
Peri-operative management: Stress-dose hydrocortisone (100 mg IV at induction) if ACTH deficient. Monitor sodium closely for DI (first 5–10 days).

Radiotherapy

Used for residual or recurrent tumour not controlled by surgery/medical therapy. Goal is tumour control, not rapid hormone normalisation (may take years).

Modality	Indication	Key Details
Stereotactic Radiosurgery (SRS) (Gamma Knife, CyberKnife)	Focal residual/recurrent adenoma <3 cm, ≥3–5 mm from optic chiasm.	Single high-dose fraction. 5-year tumour control >90%. Hypopituitarism risk 20–40% at 10 years.
Fractionated Radiotherapy (EBRT)	Larger, invasive, or recurrent tumours close to optic apparatus.	Typically 45–50 Gy in 25 fractions. Slower biochemical response. Higher long-term hypopituitarism risk (~50–80%).

Monitoring & Follow-up

Post-operative / Post-treatment

Day 1–10

Inpatient: Monitor fluid balance, serum sodium (for DI). Check morning cortisol on day 2–3. Formal visual field testing before discharge if pre-op deficit.

6–12 weeks

First outpatient review: Full pituitary function panel (cortisol, TSH/fT4, IGF-1, prolactin, LH/FSH, testosterone/oestradiol). Repeat MRI pituitary (baseline for recurrence). Visual fields if pre-op abnormal.

3–6 months

Secretory adenomas: Assess biochemical remission (normal IGF-1, UFC, prolactin). If not in remission, discuss adjuvant therapy (medical or radiotherapy).

Annually (lifelong)

All patients: Clinical assessment, pituitary hormone panel, MRI (frequency reduced after 5 years if stable). Screen for metabolic syndrome, osteoporosis, cardiovascular risk. Hypopituitarism replacement monitoring.

Special Populations

🤰

Pregnancy

Prolactinoma: Microadenomas – stop cabergoline pre-conception or at positive pregnancy test (low risk of enlargement). Macroadenomas – continue cabergoline through pregnancy if high risk of expansion; monitor visual fields each trimester.

Acromegaly: Discontinue somatostatin analogues and pegvisomant pre-conception (limited safety data). Surgery if needed in 2nd trimester.

Cushing's disease: Best managed by surgery pre-conception. If diagnosed in pregnancy, medical therapy (ketoconazole, metyrapone) may be considered under specialist supervision.

👶

Paediatrics

Rare. Most common are prolactinomas and ACTH-secreting adenomas. Surgery is first-line for most non-prolactinoma adenomas. Dopamine agonists for prolactinomas (lower doses). Monitor growth and puberty carefully.

👴

Elderly

Higher prevalence of non-functioning adenomas. Surgery may be higher risk due to comorbidities; consider medical management or watchful surveillance for slower-growing tumours. Careful assessment of hypopituitarism symptoms (often attributed to ageing).

🩺

Renal/Hepatic Impairment

Cabergoline: Use with caution in severe hepatic impairment (Child-Pugh C); no renal dose adjustment. Octreotide: No renal adjustment; caution in cirrhosis (hepatic metabolism). Pegvisomant: No data in severe renal/hepatic impairment.

🛡️

Immunocompromised

No specific pituitary adenoma considerations. Ensure vaccinations are up-to-date pre-surgery. Post-transsphenoidal surgery risk of meningitis may be slightly higher; prophylactic antibiotics per neurosurgical protocol.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander peoples may experience pituitary adenomas but face significant barriers to timely diagnosis and specialist care. These include geographical remoteness, reduced access to endocrinology and neurosurgery services, and culturally unsafe healthcare environments.

Diagnosis & Access

Delayed presentation is common, especially for macroadenomas causing visual loss. Local Health Districts and Aboriginal Medical Services (AMS) should facilitate urgent telehealth endocrinology consultations and funded travel to metropolitan pituitary centres.

Cultural Safety

Engagement with Indigenous Health Workers and Liaison Officers is essential. Patient information should be available in plain language and relevant community languages. Respect for family involvement in decision-making.

Chronic Disease Management

Post-treatment, long-term monitoring for hypopituitarism and metabolic comorbidities must be integrated into holistic primary care plans within the AMS. Ensure adequate follow-up for hormone replacement and tumour recurrence screening.

📚 References

1. Melmed S, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-88.
2. Katznelson L, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.
3. Nieman LK, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-31.
4. Freda PU, et al. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(4):894-904.
5. Australian Institute of Health and Welfare (AIHW). Brain and other central nervous system cancer. Cancer Series. 2023.
6. The Royal Australian and New Zealand College of Ophthalmologists (RANZCO). Guidelines for the management of visual field defects due to pituitary adenomas. 2020.
7. Chanson P, et al. European Society of Endocrinology (ESE) Clinical Practice Guideline on the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1-G24.
8. Fleseriu M, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847-875.
9. Australian Government Department of Health. PBS Schedule: Cabergoline, Octreotide. Accessed 2024.
10. Asa SL, et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6-26.